Patents by Inventor Stefan Peukert

Stefan Peukert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,3-substituted cyclobutyl derivatives and uses thereof
    Patent number: 11845730
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutical composition described herein.
    Type: Grant
    Filed: March 24, 2022
    Date of Patent: December 19, 2023
    Inventors: Donglei Liu, Julien Papillon, Stefan Peukert, James J. Powers
  • NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER
    Publication number: 20230203032
    Abstract: The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein A, R1 and R3 are as described herein, as well as compositions and methods of using such compounds.
    Type: Application
    Filed: November 21, 2022
    Publication date: June 29, 2023
    Inventors: Atwood Kim CHEUNG, Donglei LIU, Stefan PEUKERT, Heng GE, Yu GAI, Xingjuan CHANG
  • Naphthyridinone derivatives and their use in the treatment of arrhythmia
    Patent number: 11530213
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: December 20, 2022
    Assignee: Novartis AG
    Inventors: Guillaume Barbe, Gregory Raymond Bebernitz, Sicong Geng, Hatice Belgin Gulgeze Efthymiou, Lv Liao, Fupeng Ma, Ruowei Mo, David Thomas Parker, Yunshan Peng, Stefan Peukert, Nichola Smith, Ken Yamada, Kayo Yasoshima
  • 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF
    Publication number: 20220324811
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutical composition described herein.
    Type: Application
    Filed: March 24, 2022
    Publication date: October 13, 2022
    Inventors: Donglei LIU, Julien PAPILLON, Stefan PEUKERT, James J. POWERS
  • NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA
    Publication number: 20210284635
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: October 15, 2020
    Publication date: September 16, 2021
    Inventors: Guillaume BARBE, Gregory Raymond BEBERNITZ, Sicong GENG, Hatice Belgin GULGEZE EFTHYMIOU, Lv LIAO, Fupeng MA, Ruowei MO, David Thomas PARKER, Yunshan PENG, Stefan PEUKERT, Nichola Smith, Ken YAMADA, Kayo YASOSHIMA
  • Naphthyridinone derivatives and their use in the treatment of arrhythmia
    Patent number: 10844055
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: November 24, 2020
    Assignee: NOVARTIS AG
    Inventors: Guillaume Barbe, Gregory Raymond Bebernitz, Sicong Geng, Hatice Belgin Gulgeze Efthymiou, Lv Liao, Fupeng Ma, Ruowei Mo, David Thomas Parker, Yunshan Peng, Stefan Peukert, Ken Yamada, Kayo Yasoshima, Nichola Smith
  • NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA
    Publication number: 20190263803
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: March 1, 2019
    Publication date: August 29, 2019
    Inventors: Guillaume BARBE, Gregory Raymond BEBERNITZ, Sicong GENG, Hatice Belgin GULGEZE EFTHYMIOU, Lv LIAO, Fupeng MA, Ruowei MO, David Thomas PARKER, Yunshan PENG, Stefan PEUKERT, Ken YAMADA, Kayo YASOSHIMA
  • Naphthyridinone derivatives and their use in the treatment of arrhythmia
    Patent number: 10266531
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: April 23, 2019
    Assignee: Novartis AG
    Inventors: Guillaume Barbe, Gregory Raymond Bebernitz, Sicong Geng, Hatice Belgin Gulgeze Efthymiou, Lv Liao, Fupeng Ma, Ruowei Mo, David Thomas Parker, Yunshan Peng, Stefan Peukert, Ken Yamada, Kayo Yasoshima
  • Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
    Patent number: 10058534
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Grant
    Filed: February 17, 2018
    Date of Patent: August 28, 2018
    Assignee: Novartis AG
    Inventors: Heather Elizabeth Burks, Michael A. Dechantsreiter, Guo He, Jill Nunez, Stefan Peukert, Clayton Springer, Yingchuan Sun, Noel Marie-France Thomsen, George Scott Tria, Bing Yu
  • BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20180169063
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Application
    Filed: February 17, 2018
    Publication date: June 21, 2018
    Inventors: Heather Elizabeth BURKS, Michael A. DECHANTSREITER, Guo HE, Jill NUNEZ, Stefan PEUKERT, Clayton SPRINGER, Yingchuan SUN, Noel Marie-France THOMSEN, George Scott TRIA, Bing YU
  • NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA
    Publication number: 20180111932
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: October 19, 2017
    Publication date: April 26, 2018
    Inventors: Guillaume BARBE, Gregory Raymond BEBERNITZ, Sicong GENG, Hatice Belgin GULGEZE EFTHYMIOU, Lv LIAO, Fupeng MA, Ruowei MO, David Thomas PARKER, Yunshan PENG, Stefan PEUKERT, Ken YAMADA, Kayo YASOSHIMA
  • Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
    Patent number: 9931317
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: April 3, 2018
    Assignee: Novartis AG
    Inventors: Heather Elizabeth Burks, Michael A. Dechantsreiter, Guo He, Jill Nunez, Stefan Peukert, Clayton Springer, Yingchuan Sun, Noel Marie-France Thomsen, George Scott Tria, Bing Yu
  • BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20170112805
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Application
    Filed: January 5, 2017
    Publication date: April 27, 2017
    Inventors: Heather Elizabeth BURKS, Michael A. DECHANTSREITER, Guo HE, Jill NUNEZ, Stefan PEUKERT, Clayton SPRINGER, Yingchuan SUN, Noel Marie-France THOMSEN, George Scott TRIA, Bing YU
  • Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
    Patent number: 9561211
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: February 7, 2017
    Assignee: Novartis AG
    Inventors: Heather Elizabeth Burks, Michael A. Dechantsreiter, Guo He, Jill Nunez, Stefan Peukert, Clayton Springer, Yingchuan Sun, Noel Marie-France Thomsen, George Scott Tria, Bing Yu
  • Pyridone derivatives and uses thereof in the treatment of tuberculosis
    Patent number: 9546138
    Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the inhibition of mycolic acid biosynthesis through inhibition of M. tuberculosis Enoyl Acyl Carrier Protein Reductase enzyme (InhA): wherein R1, R2, R3, R4 and R5 are as defined herein.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: January 17, 2017
    Assignee: Novartis AG
    Inventors: Ravinder Reddy Kondreddi, Ngai Ling Ma, Stefan Peukert, Srinivasa P S Rao, Manjunatha Ujjini
  • Pyridazinyl derivatives as SMO inhibitors
    Patent number: 9409871
    Abstract: The present invention relates to compounds of formula I: in which L, W, X, Y, Z, m, p, R1, R2, R3, R4 and R7 are defined in the Summary of the Invention; capable of inhibiting the Hedgehog and Smo signaling pathway. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the diagnosis and treatment of pathologies relating to the Hedgehog and Smo signaling pathway, for example, tumor formation, cancer, neoplasia and non-malignant hyperproliferative disorders.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: August 9, 2016
    Assignee: NOVARTIS AG
    Inventors: Feng He, Stefan Peukert, Karen Marie Miller-Moslin, Naeem Yusuff, Zhuoliang Chen, Bharat Lagu
  • BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20160184265
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Application
    Filed: March 10, 2016
    Publication date: June 30, 2016
    Applicant: NOVARTIS AG
    Inventors: Heather Elizabeth BURKS, Michael A. DECHANTSREITER, Guo HE, Jill NUNEZ, Stefan PEUKERT, Clayton SPRINGER, Yingchuan SUN, Noel Marie-France THOMSEN, George Scott TRIA, Bing YU
  • Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
    Patent number: 9321746
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: April 26, 2016
    Assignee: NOVARTIS AG
    Inventors: Heather Elizabeth Burks, Michael A. Dechantsreiter, Guo He, Jill Nunez, Stefan Peukert, Clayton Springer, Yingchuan Sun, Noel Marie-France Thomsen, George Scott Tria, Bing Yu
  • BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20150361065
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Application
    Filed: February 12, 2014
    Publication date: December 17, 2015
    Applicant: Novartis AG
    Inventors: Heather Elizabeth BURKS, Michael A. DECHANTSREITER, Guo HE, Jill NUNEZ, Stefan PEUKERT, Clayton SPRINGER, Yingchuan SUN, Neoel Marie-France THOMSEN, George Scott TRIA, Bing YU
  • PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS
    Publication number: 20150291526
    Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the inhibition of mycolic acid biosynthesis through inhibition of M. tuberculosis Enoyl Acyl Carrier Protein Reductase enzyme (InhA): wherein R1, R2, R3, R4 and R5 are as defined herein.
    Type: Application
    Filed: December 12, 2013
    Publication date: October 15, 2015
    Applicant: Novartis AG
    Inventors: Ravinder Reddy KONDREDDI, Ujjini H. MANJUNATHA, Ngai Ling MA, Stefan PEUKERT, Srinivasa PS RAO